Fr1da Logo, zur Startseite

Fr1da Publikationen

2026

  • Weiss, A., Chakievska, L., Achenbach, P., Hergl, M., Hummel, S., Ott, R., Scholz, M., Winkler, C., Bonifacio, E., & Ziegler, A.-G. (2026). Stratifying the rate of disease progression by progression likelihood scores in children and adolescents with stage 1 and stage 2 type 1 diabetes in Germany. Diabetes Care, 49(2), 352–360. doi.org/10.2337/dc25-2184.
  • Koeger, M., Winkler, C., Hummel, S., Weiss, A., Koutangni, T., Yates, M., Bonnemaire, M., Guenther, O., Zaccai, J., & Ziegler, A.-G. (2026). Generalizability of progression risk in the TN-10 trial to a European population with or without a first-degree relative with type 1 diabetes. Diabetes Care, 49(3), 393–400. doi.org/10.2337/dc25-1021.
  • Standl M., Scholz M., Thiering E., Gappa M., Schikowski T., Achenbach P., Ziegler A.-G. (2026). Prevalence of early-stage type 1 diabetes in young adults: a population-based cohort study. The Lancet Diabetes & Endocrinology, 14(5), 371–373. DOI: 10.1016/S2213-8587(26)00034-3. 
  • Ziegler, A.-G., Albeer, A., Arnolds, S., Assfalg, R., Bunk, M., Daniel, C., Hofelich, A., Jacobsen, S., Kick, K., Knoop, J., Kohls, M., Kordonouri, O., Matzke, C., Pfirrmann, M., Ramminger, C., Sarcletti, K., Scholz, M., Schütte-Borkovec, K., Serr, I., … Achenbach, P. (2026). Effect of high-dose oral insulin in children with stage 1 type 1 diabetes: The Fr1da insulin intervention randomized controlled trial. Diabetes Care, 49(5), 746–754. doi.org/10.2337/dc25-2818.
  • Bonifacio, E., Scholz, M., Weiss, A., & Ziegler, A.-G. (2026). Comparison of IA-2 bridge ELISA and radiobinding assays for progression risk assessment in early-stage type 1 diabetes. Diabetes, Obesity and Metabolism, 28(5), 4409–4412. doi.org/10.1111/dom.70630.
  • Cherdron, C., Achenbach, P., Ackermann, K., Haupt, F., Heublein, A., Knopff, A., Schill, S., Schmidt, J., Stock, J., Winkler, C., Ziegler, A.-G., & Hummel, S. (2026). Health care provider perceptions of screening for early-stage type 1 diabetes—A survey study. Diabetes, Obesity and Metabolism, 28(7), 5939–5951. doi.org/10.1111/dom.70803.
  • Winkler, C., Friedl, N., Abt, R., Ackermann, K., Bently, J., Braig, S., Brämswig, S., Dunstheimer, D., Ermer, U., Ewald, D., Gerstl, E.-M., Hammersen, J., Haupt, F., Hergl, M., Hubmann, M., Hummel, S., Jochem, B., Knopff, A., Lange, K., … Ziegler, A.-G. (2026). Screening children for early-stage type 1 diabetes. JAMA, 335(23), 2046–2056. doi.org/10.1001/jama.2026.6085.
  • Weiss, A., Huber, E., Reinmüller, F., Munzinger, A., Bonifacio, E., & Ziegler, A.-G. (2026). Continuous glucose monitoring using the FreeStyle Libre Pro iQ in presymptomatic type 1 diabetes. Diabetologia. doi.org/10.1007/s00125-026-06852-w

2025

  • Achenbach, P., Berner, R., Bonifacio, E., Brämswig, S., Braig, S., Dunstheimer, D., Ermer, U., Ewald, D., Gemulla, G., Hauer, J., Haupt, F., Haus, G., Hubmann, M., Hummel, S., Kandler, M., Kordonouri, O., Lange, K., Laub, O., Lorrmann, A., … Ziegler, A.-G. (2025). Früherkennung von Typ-1-Diabetes durch Inselautoantikörper-Screening – ein Positionspapier der Fr1daPlex-Projektleiter und -Schulungszentren, des BVKJ Bayern und PaedNetz Bayern e.V. Das Gesundheitswesen, 87(1), 27–37. doi.org/10.1055/a-2320-2859.
  • von dem Berge, T., Achenbach, P., Gemulla, G., Hummel, S., Loff, A., & Kordonouri, O. (2025). Früherkennung des Typ-1-Diabetes im Kindesalter: Das Fr1da-plex-Netzwerk in Deutschland. Monatsschrift Kinderheilkunde. doi.org/10.1007/s00112-025-02202-z.
  • Hummel, S., Koeger, M., Bonifacio, E., & Ziegler, A.-G. (2025). Dysglycaemia definitions and progression to clinical type 1 diabetes in children with multiple islet autoantibodies. The Lancet Diabetes & Endocrinology, 13(1), 10–12. doi.org/10.1016/S2213-8587(24)00337-1.
  • Hoffmann, L., Kohls, M., Arnolds, S., Achenbach, P., Bergholdt, R., Bonifacio, E., Bosi, E., Gündert, M., Hoefelschweiger, B. K., Hummel, S., Jarosz-Chobot, P., Kordonouri, O., Lampasona, V., Narendran, P., Overbergh, L., Pociot, F., Raposo, J. F., Šumník, Z., Szypowska, A., … Ziegler, A.-G. (2025). EDENT1FI Master Protocol for screening of presymptomatic early-stage type 1 diabetes in children and adolescents. BMJ Open, 15(1), e088522. doi.org/10.1136/bmjopen-2024-088522.

2024

  • Hendriks, A. E. J., Marcovecchio, M. L., Besser, R. E. J., Bonifacio, E., Casteels, K., Elding Larsson, H., Gemulla, G., Lundgren, M., Kordonouri, O., Mallone, R., Pociot, F., Szypowska, A., Toppari, J., von dem Berge, T., Ziegler, A.-G., Mathieu, C., & Achenbach, P. (2024). Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes. Diabetes/Metabolism Research and Reviews, 40(2), e3777. doi.org/10.1002/dmrr.3777.
  • Bonifacio, E., Winkler, C., Achenbach, P., & Ziegler, A.-G. (2024). Effect of population-wide screening for presymptomatic early-stage type 1 diabetes on paediatric clinical care. The Lancet Diabetes & Endocrinology, 12(6), 376–378. doi.org/10.1016/S2213-8587(24)00101-3.
  • Friedl, N., Sporreiter, M., Winkler, C., Heublein, A., Haupt, F., Ziegler, A.-G., Bonifacio, E., & Fr1da Study Group. (2024). Progression from presymptomatic to clinical type 1 diabetes after COVID-19 infection. JAMA, 332(6), 501–502. doi.org/10.1001/jama.2024.11174.
  • Phillip, M., Achenbach, P., Addala, A., et al. (2024). Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetes Care, 47(8), 1276–1298. doi.org/10.2337/dci24-0042.

2023

  • Shuck, S. C., Achenbach, P., Roep, B. O., Termini, J. S., Hernandez-Castillo, C., Winkler, C., Weiss, A., & Ziegler, A.-G. (2023). Methylglyoxal products in pre-symptomatic type 1 diabetes. Frontiers in Endocrinology, 14, 1108910. doi.org/10.3389/fendo.2023.1108910.
  • Badpa, M., Schneider, A., Ziegler, A.-G., Winkler, C., Haupt, F., Wolf, K., & Peters, A. (2023). Outdoor light at night and children's body mass: A cross-sectional analysis in the Fr1da study. Environmental Research, 232, 116325. doi.org/10.1016/j.envres.2023.116325.
  • Hummel, S., Carl, J., Friedl, N., Winkler, C., Kick, K., Stock, J., Reinmüller, F., Ramminger, C., Schmidt, J., Lwowsky, D., Braig, S., Dunstheimer, D., Ermer, U., Gerstl, E. M., Weber, L., Nellen-Hellmuth, N., Brämswig, S., Sindichakis, M., Tretter, S., … Achenbach, P. (2023). Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation. Diabetologia, 66(9), 1633–1642. doi.org/10.1007/s00125-023-05953-0.
  • Lugar, M., Eugster, A., Achenbach, P., von dem Berge, T., Berner, R., Besser, R. E. J., Casteels, K., Elding Larsson, H., Gemulla, G., Kordonouri, O., Lindner, A., Lundgren, M., Müller, D., Oltarzewski, M., Rochtus, A., Scholz, M., Szypowska, A., Todd, J. A., Ziegler, A.-G., Bonifacio, E., & GPPAD Study Group. (2023). SARS-CoV-2 infection and development of islet autoimmunity in early childhood. JAMA, 330(12), 1151–1160. doi.org/10.1001/jama.2023.16348.
  • Hummel, S., Friedl, N., Winkler, C., Ziegler, A.-G., & Achenbach, P.; Fr1da Study Group. (2023). Presymptomatic type 1 diabetes and disease severity at onset: Reply to Schneider J, Gemulla G, Kiess W et al [letter]. Diabetologia, 66(12), 2389–2390. doi.org/10.1007/s00125-023-06017-z.
  • Hofelich, A., Marcus, B. A., & Achenbach, P. (2023). Früherkennung und Prävention des Typ-1-Diabetes: Entstehen und Fortschreiten des Autoimmunprozesses verhindern oder verzögern. Diabetes Aktuell, 21(1), 12–28. doi.org/10.1055/a-2012-3790.

2022

  • Karl, F. M., Winkler, C., Ziegler, A.-G., Laxy, M., & Achenbach, P. (2022). Costs of public health screening of children for presymptomatic type 1 diabetes in Bavaria, Germany. Diabetes Care, 45(4), 837–844. doi.org/10.2337/dc21-1648.
  • Badpa, M., Wolf, K., Schneider, A., Winkler, C., Haupt, F., Peters, A., & Ziegler, A.-G. (2022). Association of long-term environmental exposures in pregnancy and early life with islet autoimmunity development in children in Bavaria, Germany. Environmental Research, 212, 113503. doi.org/10.1016/j.envres.2022.113503.
  • Ott, R., Achenbach, P., Ewald, D. A., Friedl, N., Gemulla, G., Hubmann, M., Kordonouri, O., Loff, A., Marquardt, E., Sifft, P., Sporreiter, M., Zapardiel-Gonzalo, J., & Ziegler, A.-G. (2022). SARS-CoV-2 seroprevalence in preschool and school-age children—Population screening findings from January 2020 to June 2022. Deutsches Ärzteblatt International, 119(45), 765–770. doi.org/10.3238/arztebl.m2022.0355.
  • Rewers, M., Bonifacio, E., Ewald, D., Rasmussen, C. G., Jia, X., Pyle, L., & Ziegler, A.-G. (2022). SARS-CoV-2 infections and presymptomatic type 1 diabetes autoimmunity in children and adolescents from Colorado, USA, and Bavaria, Germany. JAMA, 328(12), 1252–1255. doi.org/10.1001/jama.2022.14092.
  • Weiss, A., Zapardiel-Gonzalo, J., Voss, F., Jolink, M., Stock, J., Haupt, F., Kick, K., Welzhofer, T., Heublein, A., Winkler, C., Achenbach, P., Ziegler, A.-G., & Bonifacio, E. (2022). Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening. Diabetologia, 65(12), 2121–2131. doi.org/10.1007/s00125-022-05780-9.
  • Weiss, A., Zapardiel-Gonzalo, J., Voss, F., Jolink, M., Stock, J., Haupt, F., Kick, K., Welzhofer, T., Heublein, A., Winkler, C., Achenbach, P., Ziegler, A.-G., Bonifacio, E., & Fr1da-study group. (2022). Correction to: Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening. Diabetologia, 65, 2175. doi.org/10.1007/s00125-022-05798-z
  • Hofelich, A., Marcus, B. A., & Achenbach, P. (2022). Früherkennung und Prävention des Typ-1-Diabetes. Diabetologie und Stoffwechsel, 17(6), 445–460. doi.org/10.1055/a-0894-1860.
  • Achenbach, P. (2022). Typ-1-Diabetes bei Kindern früh erkennen und präventiv handeln: Die Fr1da-Studie. Diabetes aktuell, 20(3), 116–123. doi.org/10.1055/a-1839-8893.

2021

  • Hippich, M., Holthaus, L., Assfalg, R., Zapardiel-Gonzalo, J., Kapfelsperger, H., Heigermoser, M., Haupt, F., Ewald, D. A., Welzhofer, T. C., Marcus, B. A., Heck, S., Koelln, A., Stock, J., Voss, F., Secchi, M., Piemonti, L., de la Rosa, K., Protzer, U., Boehmer, M., … Ziegler, A.-G. (2021). A public health antibody screening indicates a 6-fold higher SARS-CoV-2 exposure rate than reported cases in children. Med, 2(2), 149–163.e4. doi.org/10.1016/j.medj.2020.10.003.
  • Hippich, M., Sifft, P., Zapardiel-Gonzalo, J., Böhmer, M. M., Lampasona, V., Bonifacio, E., & Ziegler, A.-G. (2021). A public health antibody screening indicates a marked increase of SARS-CoV-2 exposure rate in children during the second wave. Med, 2(5), 571–572. doi.org/10.1016/j.medj.2021.03.019.

2020

  • Ziegler, A.-G., Kick, K., Bonifacio, E., Haupt, F., Hippich, M., Dunstheimer, M., Lang, M., Laub, O., Warncke, K., Lange, K., Assfalg, R., Jolink, M., Winkler, C., Achenbach, P., & Fr1da Study Group. (2020). Yield of a public health screening of children for islet autoantibodies in Bavaria, Germany. JAMA, 323(4), 339–351. doi.org/10.1001/jama.2019.21565.
  • Marcus, B. A., Achenbach, P., & Ziegler, A.-G. (2020). Typ-1-Diabetes: Früherkennung und Ansätze zur Prävention: Update 2020. Diabetologe, 16(7), 654–661. doi.org/10.1007/s11428-020-00668-x.

2019

  • Kick, K., Hoffmann, V. S., Lange, K., Lang, M., Laub, O., Bechtold-Dalla Pozza, S., Böcker, D., Braig, S., Dietz, B., Dunstheimer, D., Eber, S., Ermer, U., Gavazzeni, A., Gerstl, E. M., Götz, M., Huhn, F., Kuhnle-Krahl, U., Landendörfer, W., Leipold, G., … Ziegler, A.-G. (2019). Feasibility and organization of a population-based screening for pre-symptomatic type 1 diabetes in children—Evaluation of the Fr1da study. Journal of Public Health, 27(5), 553–560. doi.org/10.1007/s10389-018-0981-x.

2018

  • Achenbach, P. (2018). Typ-1-Diabetes im asymptomatischen Frühstadium: Orales Insulin zur präventiven Behandlung. Diabetologie, 14, 234–239. DOI: 10.1007/s11428-018-0341-z.
  • Winkler, C., Kick, K., Haupt, F., & Assfalg, R. (2018). Früherkennung des Typ-1-Diabetes in der Fr1da-Studie: Diagnosestellung im asymptomatischen Stadium. Diabetologie, 14(4), 214–220. doi.org/10.1007/s11428-018-0336-9.
  • Beyerlein, A., & Jolink, M. (2018). Evaluation of the Fr1da screening: From an epidemiological perspective. Diabetologie, 14(4), 221–223.
  • Achenbach, P. (2018). Typ-1-Diabetes im asymptomatischen Frühstadium: Orales Insulin zur präventiven Behandlung. Diabetologie, 14(4), 234–239. doi.org/10.1007/s11428-018-0341-z.
  • Warncke, K., Flores, D., Heinrich, M., Aydin, S. E., & Burdach, S. (2018). Behandlung des Typ-1-Diabetes im Frühstadium: Eine Kasuistik. Diabetologie, 14(4), 231–233. doi.org/10.1007/s11428-018-0342-y.
  • Kick, K., Assfalg, R., Aydin, S., Bechtold-Dalla Pozza, S., et al. (2018). Recruiting young pre-symptomatic children for a clinical trial in type 1 diabetes: Insights from the Fr1da insulin intervention study. Contemporary Clinical Trials Communications, 11, 170–173. doi.org/10.1016/j.conctc.2018.08.004.
  • Heinrich, M., Maison, N., Achenbach, P., Assfalg, R., Braig, S., Böcker, D., Dunstheimer, D., Ermer, U., Gavazzeni, A., Gerstl, E.-M., Hummel, S., Kick, K., Müller, H., Nellen-Hellmuth, N., Ockert, C., Sindichakis, M., Tretter, S., Warncke, K., Ziegler, A.-G., & Beyerlein, A. (2018). Fasting hypoglycemia is associated with disease progression in presymptomatic early stage type 1 diabetes. Pediatric Diabetes, 19(7), 1238–1242. doi.org/10.1111/pedi.12739.
  • Achenbach, P. (2018). Früherkennung und präventive Behandlung des Typ-1-Diabetes. Diabetologie, 14(4), 212–213. doi.org/10.1007/s11428-018-0344-9.

2016

  • Raab, J., Haupt, F., Scholz, M., Matzke, C., Warncke, K., Lange, K., et al. (2016). Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: Design and initial results of the Fr1da study. BMJ Open, 6(5), e011144. doi.org/10.1136/bmjopen-2016-011144.
  • Zillmer, S., Warncke, K., Raab, J., Winkler, C., Haupt, F., Seithe, H., Frank, I., Nellen-Hellmuth, N., Sommer, C., Lange, K., Achenbach, P., & Ziegler, A.-G. (2016). Kinder mit Frühstadium des Typ-1-Diabetes: Drei Fallberichte aus der Fr1da-Studie. Diabetes, Stoffwechsel und Herz, 25(2), 79–83.
  • Ziegler, A.-G., Haupt, F., Scholz, M., Weininger, K., Wittich, S., Löbner, S., Matzke, C., Gezginci, C., Riethausen, S., Beyerlein, A., Zillmer, S., Amoroso, M., Coles, R., Powell, M., Furmaniak, J., Smith, B. R., Winkler, C., Bonifacio, E., & Achenbach, P. (2016). 3 Screen ELISA for high-throughput detection of beta cell autoantibodies in capillary blood. Diabetes Technology & Therapeutics, 18(11), 687–693. doi.org/10.1089/dia.2016.0199.

2015

  • Insel, R. A., Dunne, J. L., & Ziegler, A.-G. (2015). General population screening for type 1 diabetes: Has its time come? Current Opinion in Endocrinology, Diabetes and Obesity, 22(4), 270–276.
  • Raab, J., Warncke, K., Haupt, F., Winkler, C., Löbner, S., Lang, M., Laub, O., Lange, K., Achenbach, P., & Ziegler, A.-G. (2015/2016). Diabetes mellitus Typ 1 bei Kindern früh erkennen und behandeln. Die Fr1da-Studie. pädiatrische praxis, 85, 213–222.